CN101547924B - 抑制有丝分裂的化合物 - Google Patents

抑制有丝分裂的化合物 Download PDF

Info

Publication number
CN101547924B
CN101547924B CN2007800423837A CN200780042383A CN101547924B CN 101547924 B CN101547924 B CN 101547924B CN 2007800423837 A CN2007800423837 A CN 2007800423837A CN 200780042383 A CN200780042383 A CN 200780042383A CN 101547924 B CN101547924 B CN 101547924B
Authority
CN
China
Prior art keywords
cancer
compound
group
cell
benzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800423837A
Other languages
English (en)
Chinese (zh)
Other versions
CN101547924A (zh
Inventor
克里斯托弗·F·克莱本
托德·B·塞尔斯
斯蒂芬·G·斯特劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101547924(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to CN201310367332.9A priority Critical patent/CN103483343B/zh
Publication of CN101547924A publication Critical patent/CN101547924A/zh
Application granted granted Critical
Publication of CN101547924B publication Critical patent/CN101547924B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2007800423837A 2006-11-16 2007-11-14 抑制有丝分裂的化合物 Active CN101547924B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310367332.9A CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
US60/859,340 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310367332.9A Division CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Publications (2)

Publication Number Publication Date
CN101547924A CN101547924A (zh) 2009-09-30
CN101547924B true CN101547924B (zh) 2013-09-25

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800423837A Active CN101547924B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物
CN201310367332.9A Active CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310367332.9A Active CN103483343B (zh) 2006-11-16 2007-11-14 抑制有丝分裂的化合物

Country Status (34)

Country Link
US (7) US8026246B2 (cg-RX-API-DMAC10.html)
EP (4) EP2497773B1 (cg-RX-API-DMAC10.html)
JP (3) JP5102839B2 (cg-RX-API-DMAC10.html)
KR (2) KR101110458B1 (cg-RX-API-DMAC10.html)
CN (2) CN101547924B (cg-RX-API-DMAC10.html)
AR (1) AR064246A1 (cg-RX-API-DMAC10.html)
AT (1) ATE556076T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007322046B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718803B8 (cg-RX-API-DMAC10.html)
CA (1) CA2669680C (cg-RX-API-DMAC10.html)
CL (1) CL2007003244A1 (cg-RX-API-DMAC10.html)
CR (3) CR10782A (cg-RX-API-DMAC10.html)
CY (1) CY1112828T1 (cg-RX-API-DMAC10.html)
DK (2) DK2086981T3 (cg-RX-API-DMAC10.html)
EA (1) EA015779B1 (cg-RX-API-DMAC10.html)
ES (3) ES2384123T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20125459B (cg-RX-API-DMAC10.html)
HR (2) HRP20120490T1 (cg-RX-API-DMAC10.html)
IL (1) IL198690A0 (cg-RX-API-DMAC10.html)
MA (1) MA30988B1 (cg-RX-API-DMAC10.html)
MX (3) MX348568B (cg-RX-API-DMAC10.html)
MY (1) MY153243A (cg-RX-API-DMAC10.html)
NO (1) NO343338B1 (cg-RX-API-DMAC10.html)
NZ (3) NZ611898A (cg-RX-API-DMAC10.html)
PH (1) PH12012502057B1 (cg-RX-API-DMAC10.html)
PL (2) PL2497772T3 (cg-RX-API-DMAC10.html)
PT (2) PT2086981E (cg-RX-API-DMAC10.html)
RS (2) RS52313B (cg-RX-API-DMAC10.html)
SG (2) SG10201503350TA (cg-RX-API-DMAC10.html)
SI (2) SI2086981T1 (cg-RX-API-DMAC10.html)
TW (1) TWI401255B (cg-RX-API-DMAC10.html)
UA (1) UA94129C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008063525A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200903279B (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2585465B1 (en) * 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6966425B2 (ja) 2015-09-09 2021-11-17 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Hp1の機能に着目した抗癌剤のスクリーニング方法及び評価系
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20250228848A1 (en) 2022-04-07 2025-07-17 Eli Lilly And Company Process for making a kras g12c inhibitor
CA3247183A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
KR20250027777A (ko) 2022-06-30 2025-02-27 일라이 릴리 앤드 캄파니 암을 치료하기 위한 kras g12c 억제제
IL327467A (en) 2023-10-03 2026-05-01 Takeda Pharmaceutical Co Limited Elisartib and paclitaxel for the treatment of small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) * 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
HUP0401107A3 (en) 2001-08-09 2004-10-28 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR101792651B1 (ko) 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2007076348A2 (en) 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
JP5452811B2 (ja) 2014-03-26
HK1134672A1 (en) 2010-05-07
BRPI0718803B1 (pt) 2020-11-17
PT2497772E (pt) 2015-02-05
ZA200903279B (en) 2010-07-28
MX348568B (es) 2017-06-20
RS53788B1 (sr) 2015-06-30
KR20090091173A (ko) 2009-08-26
BRPI0718803B8 (pt) 2021-05-25
PL2086981T3 (pl) 2012-09-28
WO2008063525A1 (en) 2008-05-29
IL198690A0 (en) 2010-02-17
DK2086981T3 (da) 2012-08-06
EP2086981A1 (en) 2009-08-12
AR064246A1 (es) 2009-03-25
ES2528793T3 (es) 2015-02-12
PH12012502057A1 (en) 2015-09-14
EP2944639A1 (en) 2015-11-18
MA30988B1 (fr) 2009-12-01
US20150166545A1 (en) 2015-06-18
MY153243A (en) 2015-01-29
HRP20120490T1 (hr) 2012-07-31
MX343391B (es) 2016-11-04
SI2086981T1 (sl) 2012-12-31
KR101342014B1 (ko) 2013-12-19
US9765076B2 (en) 2017-09-19
US20240400567A1 (en) 2024-12-05
US20210214361A1 (en) 2021-07-15
US20190031662A1 (en) 2019-01-31
CR10782A (es) 2009-06-24
NZ577042A (en) 2012-03-30
NO343338B1 (no) 2019-02-04
NZ611898A (en) 2015-01-30
SI2497772T1 (sl) 2015-03-31
US8026246B2 (en) 2011-09-27
EP2497772A1 (en) 2012-09-12
NO20091864L (no) 2009-06-15
PL2497772T3 (pl) 2015-05-29
CL2007003244A1 (es) 2008-04-04
AU2007322046A1 (en) 2008-05-29
HK1175777A1 (en) 2013-07-12
RS52313B (sr) 2012-12-31
US10836766B2 (en) 2020-11-17
GEP20125459B (en) 2012-03-26
EP2497773A1 (en) 2012-09-12
US20110312943A1 (en) 2011-12-22
JP5102839B2 (ja) 2012-12-19
EA200970486A1 (ru) 2009-10-30
EP2497773B1 (en) 2015-02-25
US20080167292A1 (en) 2008-07-10
EP2086981B1 (en) 2012-05-02
CN103483343B (zh) 2016-06-01
SG10201503350TA (en) 2015-06-29
NZ597252A (en) 2013-06-28
ES2384123T3 (es) 2012-06-29
CR20140544A (es) 2015-01-12
JP2014055166A (ja) 2014-03-27
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
EP2497772B1 (en) 2014-10-29
AU2007322046B2 (en) 2012-04-05
TWI401255B (zh) 2013-07-11
CA2669680C (en) 2012-04-10
US11958855B2 (en) 2024-04-16
HK1175778A1 (en) 2013-07-12
CA2669680A1 (en) 2008-05-29
ATE556076T1 (de) 2012-05-15
CN101547924A (zh) 2009-09-30
TW200829589A (en) 2008-07-16
UA94129C2 (ru) 2011-04-11
EP2944639B1 (en) 2017-01-04
CN103483343A (zh) 2014-01-01
US20110312942A1 (en) 2011-12-22
DK2497772T3 (en) 2015-01-19
EA015779B1 (ru) 2011-12-30
CY1112828T1 (el) 2016-02-10
BRPI0718803A2 (pt) 2013-12-03
HRP20150047T1 (en) 2015-03-13
JP2012006965A (ja) 2012-01-12
KR101110458B1 (ko) 2012-03-13
KR20110113210A (ko) 2011-10-14
JP2010510215A (ja) 2010-04-02
CR20140154A (es) 2014-07-23
HK1217699A1 (en) 2017-01-20
SG176443A1 (en) 2011-12-29
ES2537451T3 (es) 2015-06-08
PH12012502057B1 (en) 2018-10-24
US9988384B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
CN101547924A (zh) 抑制有丝分裂的化合物
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
CN102803269A (zh) Ampk的噻吩并[2,3-b]嘧啶二酮活化剂及其治疗用途
KR20090130104A (ko) 암 치료를 위한 pi3k-알파의 억제제로서의 피리도〔2,3­d〕피리미딘­7­온 화합물
JP2009539865A (ja) 置換3−アミノ−チエノ[2,3−b]ピリジン2−カルボン酸アミド化合物及び製造方法及びそれらの使用
CN118994163A (zh) 含有并环结构的化合物
CN113620976B (zh) 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
AU2012203952B2 (en) Compounds for inhibiting mitotic progression
HK1217699B (en) Compound for inhibiting mitotic progression
HK1134672B (en) Compounds for inhibiting mitotic progression
AU2014280932A1 (en) Compounds for inhibiting mitotic progression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant